foxo4-dri senolytic peptide human trial 2024 2025 Senotherapy for chronic lung disease The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Cellular Senescence in Health, Disease, and Lens Aging Full article: Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link CHK2 USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis PNAS
Pay in 4 interest-free payments of $7.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10





